Vaccine Application Extends Life of Metastatic Prostate Cancer Patients
|
By LabMedica International staff writers Posted on 24 Feb 2010 |
|
In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to trigger an immune system attack on prostate tumor cells lived considerably longer than patients who received a placebo vaccine.
The study's findings were published by the Journal of Clinical Oncology on its website in January 2010, and scheduled for later print publication. The randomized phase II study was performed by researchers from the Dana-Farber Cancer Institute (Boston, MA, USA) and affiliated organizations. The study involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of prostate specific antigen (PSA)--a protein on the surface of prostate cells that is abnormal in many prostate cancers--and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells.
The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine, produced by BN ImmunoTherapeutics, Inc. (Mountain View, CA, USA), and 40 received a placebo.
At the three-year point after the study, 30% of the PROSTVAC-VF patients were alive, versus 17% of the control group. The median survival of the vaccine group was 24.5 months, compared to 16 months for the control group, an 8.5-month increase.
Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea. "Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach,” said lead investigator and lead author Philip Kantoff, M.D., of Dana-Farber, who helped design the trial.
Investigators are now planning a phase III trial that will enroll about 600 patients to evaluate further the vaccine's effectiveness.
Related Links:
Dana-Farber Cancer Institute
BN ImmunoTherapeutics
The study's findings were published by the Journal of Clinical Oncology on its website in January 2010, and scheduled for later print publication. The randomized phase II study was performed by researchers from the Dana-Farber Cancer Institute (Boston, MA, USA) and affiliated organizations. The study involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of prostate specific antigen (PSA)--a protein on the surface of prostate cells that is abnormal in many prostate cancers--and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells.
The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine, produced by BN ImmunoTherapeutics, Inc. (Mountain View, CA, USA), and 40 received a placebo.
At the three-year point after the study, 30% of the PROSTVAC-VF patients were alive, versus 17% of the control group. The median survival of the vaccine group was 24.5 months, compared to 16 months for the control group, an 8.5-month increase.
Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea. "Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach,” said lead investigator and lead author Philip Kantoff, M.D., of Dana-Farber, who helped design the trial.
Investigators are now planning a phase III trial that will enroll about 600 patients to evaluate further the vaccine's effectiveness.
Related Links:
Dana-Farber Cancer Institute
BN ImmunoTherapeutics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Aspiration System
VACUSAFE
Latest BioResearch News
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
- Population-Scale Proteomics Study Identifies New Genetic-Protein Links
- Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
- Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
Channels
Clinical Chemistry
view channel
Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more
Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read moreMolecular Diagnostics
view channel
AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. Identifying these patients earlier could reduce the costs of ineffective... Read more
New Variant Tracking Option Expands Molecular Residual Disease Monitoring
Molecular residual disease (MRD) testing can detect traces of cancer that persist after treatment or emerge during recurrence. Because circulating tumor DNA (ctDNA) may be present at very low levels, residual... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read more
Pathology
view channel
AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more
AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
Tempus AI (Chicago, IL, USA) will present findings from a study evaluating an artificial intelligence (AI)-enabled pre-screening panel for advanced non-small cell lung cancer (NSCLC) at the ESMO Congress... Read more
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read moreTechnology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Industry
view channel
Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. Its progressive effects on memory, thinking, behavior, and daily functioning underscore... Read more
